WCN26-2509 Regression of uremic tumoral calcinosis following etelcalcetide therapy in hemodialysis patients

Read full text Summarise with VIRAT
Authors: Takuya Hase, Shunsuke Goto, Tomoaki Fukui, Hitomi Hara, Keisuke Oe, Hideki Fujii
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Uremic tumoral calcinosis is an uncommon but clinically significant complication in patients with end-stage kidney disease. It is characterized by the deposition of large calcified masses in periarticular soft tissues, leading to pain, fractures, restricted mobility, and impaired quality of life. Previous reports have indicated that severe hyperphosphatemia and/or hypercalcemia play a central role in its pathogenesis and that correction of these abnormalities may induce regression. However, therapeutic strategies for patients without marked calcium-phosphate imbalance have rarely been described.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Dermatological and Skeletal Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104199–104199
Publication date
25 March 2026
Language
EN